Ulta Lab Tests

Drug Monitoring

Drug monitoring uses laboratory testing to check medication adherence, substance use, or abstinence over time. It is widely used in pain management, addiction treatment (MAT), workplace and safety programs, and clinical care. A proactive plan starts with a clear goal (adherence, recent use, long-term pattern), chooses the right specimen (urine, oral fluid, blood, hair), and pairs a rapid screen with definitive confirmation when results are non-negative or policy requires it.

Screening immunoassays are fast and cost-effective, but they can cross-react. LC-MS/MS or GC-MS confirmation identifies the specific drug and metabolite at set cutoffs. Metabolite patterns (for example, 6-MAM for heroin; norfentanyl for fentanyl; EDDP for methadone; norbuprenorphine for buprenorphine) add clarity. Specimen validity checks help detect dilution or adulteration. Lab results inform clinical or program decisions but do not, by themselves, determine impairment or intent.

Signs, Situations & Related Needs

  • Pain management / MAT: verify adherence, detect undisclosed substances, support treatment adjustments

  • Workplace / safety-sensitive roles: pre-employment, random, return-to-duty, post-incident testing

  • Clinical care: unexpected behaviors, medication interactions, high-risk prescriptions (e.g., opioids, benzodiazepines)

  • Legal / compliance: court-ordered monitoring, child custody, probation requirements

  • When to seek urgent care: suspected overdose, severe sedation, chest pain, suicidal ideation, or rapidly worsening symptoms
    All testing should be interpreted by a qualified clinician, Medical Review Officer (MRO), or program administrator.

Why These Tests Matter

What monitoring can do

  • Verify presence or absence of target drugs and confirm specific compounds with metabolites

  • Differentiate adherence vs. non-adherence and identify undisclosed substances

  • Provide objective trends over time to guide frequency, counseling, or program steps

What monitoring cannot do

  • Prove impairment, exact dose, or time of ingestion

  • Replace clinical judgment, chain-of-custody, or program policies

  • Explain intent—results require context

What These Tests Measure (at a glance)

  • Opioids & semisynthetics: morphine, codeine, 6-MAM (heroin), hydrocodone/hydromorphone, oxycodone/oxymorphone, fentanyl/norfentanyl, methadone/EDDP, buprenorphine/norbuprenorphine

    • Use: adherence (MAT/pain), diversion concerns, undisclosed opioid exposure

  • Stimulants: amphetamine/methamphetamine (option for D/L isomer), MDMA/MDA, methylphenidate metabolites

    • Use: clarify screen cross-reactivity; confirm specific stimulant

  • Cocaine: benzoylecgonine, ecgonine methyl ester

    • Use: definitive cocaine exposure

  • Cannabinoids: THC-COOH (urine), parent THC (blood/oral fluid)

    • Use: recent vs. residual pattern by matrix

  • Benzodiazepines: alprazolam/α-hydroxyalprazolam, lorazepam, oxazepam, temazepam, clonazepam/7-aminoclonazepam

    • Use: detect glucuronidated benzos that screens may miss

  • Other classes (as ordered): barbiturates, PCP, synthetic opioids/novel psychoactives, etc.

  • Specimen validity: urine creatinine, specific gravity, pH, oxidants/nitrites

    • Use: detect dilution, substitution, or adulteration

Detection windows (typical; vary by dose/use/cutoff)

  • Urine: ~1–3 days for many drugs; longer for THC with frequent use

  • Oral fluid: hours to ~1–2 days (recent use)

  • Blood: hours to ~1 day (current presence)

  • Hair: weeks to months (long-term pattern; not impairment)

How the Testing Process Works

  1. Define the goal & policy: adherence, abstinence, recent use, or long-term pattern; confirm matrix and any chain-of-custody needs

  2. Collect the specimen: urine/oral fluid/blood/hair per instructions; add specimen validity for urine when required

  3. Screen, then confirm: run immunoassay screen; LC-MS/MS or GC-MS confirmation for non-negative or policy-directed classes

  4. Review & document: receive a secure report with analytes, metabolites, levels (and validity metrics when applicable)

  5. Trend over time: set an interval for repeat testing to document change, adherence, or relapse prevention

Interpreting Results (General Guidance)

  • Confirmed positive: target analyte(s) at/above cutoff; evaluate metabolite profile (e.g., oxycodone with oxymorphone, fentanyl with norfentanyl) and prescriptions

  • Negative / below cutoff: analyte not detected or under threshold; does not exclude use outside the detection window

  • Special markers: 6-MAM (heroin), norfentanyl (fentanyl), EDDP (methadone metabolism), norbuprenorphine(buprenorphine metabolism) strengthen interpretation

  • Matrix matters: oral fluid/blood reflect recent use; urine reflects clearance window; hair shows long-term patterns
    Always interpret alongside medications, timing, clinical findings, and program rules.

Choosing Panels vs. Individual Tests

  • Pain management / MAT: targeted opioid benzodiazepine panels with metabolite confirmation and urine validity

  • Workplace / safety programs: standard multi-drug panels (DOT/non-DOT) with confirmation as required

  • Clinical surprises (unexpected screen): broaden to LC-MS/MS confirmation panel; consider isomer testing for amphetamines

  • Long-term pattern monitoring: hair panels; pair with periodic urine/oral fluid for near-term checks

  • Suspected tampering: add specimen validity to urine panels

FAQs

What’s the difference between screening and confirmation?
Screening is a rapid yes/no immunoassay; confirmation uses mass spectrometry to precisely identify and quantify drugs/metabolites.

Can prescription meds trigger a positive screen?
Yes. That is why confirmation is used to separate cross-reactivity from true positives.

Does a positive mean I was impaired?
No. Results show presence above a cutoff, not impairment or exact timing.

Which specimen should I choose?
Match the test to the goal: blood (now), oral fluid (recent), urine (recent/clearance), hair (weeks–months pattern).

How do metabolite patterns help?
They verify biologic processing (e.g., 6-MAM for heroin) and help distinguish adherence from non-prescribed use.

What if I suspect dilution or adulteration?
Order specimen validity (creatinine, specific gravity, pH, oxidants) and follow collection policy.

Internal Links & Cross-References

  • Drug & Alcohol Tests Hub

  • Employment & Compliance Testing

  •  Pain Management Monitoring

  • Drug & Alcohol Tests Hub

  • Drug Screening

  • Drug Confirmation Test

  • Drug Monitoring

  • Drug Toxicology Monitoring

  • Alcohol

  • Key Lab Tests: LC-MS/MS Multi-Drug Panel (Urine) • Oral Fluid Drug Panel • Hair Drug Panel • Opioid/Benzodiazepine Targeted Confirmation • Fentanyl/Norfentanyl Confirmation • Specimen Validity

References

  1. Substance Abuse and Mental Health Services Administration (SAMHSA). Drug testing guidance and cutoffs.

  2. U.S. Department of Transportation (DOT). Drug Testing Program regulations.

  3. American Society of Addiction Medicine (ASAM). Appropriate use of drug testing in clinical addiction medicine.

  4. American Association for Clinical Chemistry (AACC). Laboratory best practices for definitive drug testing.

  5. College of American Pathologists (CAP). Toxicology and mass spectrometry standards.

  6. Centers for Disease Control and Prevention (CDC). Opioid prescribing and risk mitigation—monitoring considerations.

  7. ARUP Consult/clinical toxicology compendia. Detection windows, metabolite interpretation, and specimen validity.

Available Tests & Panels

Your drug monitoring menu is pre-populated in the Ulta Lab Tests system. Select the matrix and panel that match your goal and policy, pair screening with confirmatory LC/GC-MS when required, and include specimen validity for urine. Review all results with your clinician, MRO, or program administrator.

  • Page
  • 2
  • of
  • 6
  • Total Rows
  • 139
Name Matches
Blood
Blood Draw
Add to  

The Lamotrigine Test evaluates serum levels of lamotrigine to monitor drug therapy in patients with epilepsy or bipolar disorder. Abnormal concentrations may signal toxicity, inadequate dosing, or altered drug metabolism. This test aids in optimizing treatment response, assessing therapeutic balance, and ensuring systemic health in managing neurological and mood-related conditions.

Blood
Blood Draw
Add to  

The Lithium Test measures lithium levels in blood to monitor treatment for bipolar disorder and ensure safe, effective dosing. Too much lithium can cause toxicity with symptoms like nausea, tremors, or confusion, while low levels may reduce effectiveness. Doctors regularly order this test for patients taking lithium therapy. Results help maintain therapeutic range, prevent complications, and guide medication adjustments for mental health management.

Blood
Blood Draw
Also Known As: Lithium Blood Test, Lithium Serum Test, Bipolor Disorder Medication Test
Add to  

The Lithium RBC Test measures lithium levels inside red blood cells, offering a more stable reflection of long-term exposure compared to serum testing. Lithium is used in the treatment of bipolar disorder and other mood conditions, and monitoring intracellular levels helps evaluate therapeutic effectiveness, detect toxicity, and guide dose adjustments. This test provides insight into psychiatric care, drug monitoring, and patient safety.

Other
Phlebotomist
Add to  
Blood
Blood Draw
Add to  
Blood
Blood Draw
Add to  
Blood
Blood Draw
Add to  
Blood
Blood Draw
Add to  
Add to  

The Tacrolimus Highly Sensitive Test measures precise levels of tacrolimus, an immunosuppressant commonly prescribed after organ transplantation. Maintaining the right drug concentration is essential to prevent rejection while avoiding toxicity. This sensitive blood test helps doctors adjust dosage, monitor therapy effectiveness, and ensure safe long-term management for kidney, liver, heart, and lung transplant patients requiring tacrolimus treatment.

Blood
Blood Draw
Also Known As: Tacrolimus Test
Add to  

The Theophylline Test measures blood levels of theophylline, a bronchodilator used to manage asthma, COPD, and chronic bronchitis. Monitoring levels ensures therapeutic effectiveness while reducing risks of toxicity, which can cause nausea, arrhythmias, or seizures. This test supports dosage adjustment, evaluates drug interactions, and guides long-term management of respiratory disorders requiring theophylline therapy.

Blood
Blood Draw
Add to  

The Thiopurine Metabolites Test evaluates active metabolites of thiopurine drugs, including 6-thioguanine nucleotides and 6-methylmercaptopurine, to assess treatment effectiveness and safety. Elevated or low metabolite levels may indicate risk of toxicity, under-dosing, or non-adherence. This test provides critical insight for managing patients on immunosuppressive therapy, guiding personalized dosing, and monitoring long-term response.

Blood
Blood Draw
Also Known As: 6 MMP Test, 6 Tg Test
Add to  
Blood
Blood Draw
Add to  
Blood
Blood Draw
Add to  
Add to  
Blood
Blood Draw
Add to  

The Topiramate Test measures blood concentrations of topiramate, an anticonvulsant used to manage epilepsy, seizures, and migraine prevention. Monitoring levels helps evaluate therapeutic response, adjust dosing, and avoid toxicity or subtherapeutic results. This test supports individualized treatment in patients with seizure disorders, chronic migraines, or those on multi-drug regimens where drug interactions affect metabolism.

Blood
Blood Draw
Add to  

The TPMT Activity Test measures thiopurine S-methyltransferase enzyme activity to assess how a patient metabolizes thiopurine drugs. Abnormal results may indicate low or absent activity, increasing risk for toxicity from medications such as azathioprine, 6-mercaptopurine, or 6-thioguanine. This test supports safe dosing, helps prevent bone marrow suppression, and guides individualized therapy for autoimmune disease or leukemia.

Blood
Blood Draw
Also Known As: Azathioprine Toxicity Test, Mercaptopurine Toxicity Test, TPMT Deficiency Test
Add to  

The Carbohydrate-deficient Transferrin Test measures abnormal transferrin isoforms in the blood, which can indicate chronic alcohol consumption or alcohol use disorder. By detecting elevated CDT levels, the test helps assess patterns of heavy drinking and monitor abstinence or relapse. Clinicians may also use results to support evaluation of liver function and alcohol-related health risks, providing valuable insight into long-term alcohol exposure.

Blood
Blood Draw
Also Known As: Alcohol Use Test
Add to  
Blood
Blood Draw
Add to  
Blood
Blood Draw
Add to  
Blood
Blood Draw
Add to  
Blood
Blood Draw
Add to  
Blood
Blood Draw
Add to  

The Base Panel Urine Drug Screen screens a multi-drug panel in urine using immunoassay methods to detect commonly monitored substances above threshold levels. The panel includes drugs such as amphetamines, benzodiazepines, cocaine, opioids, and more. This broad screening test is widely used in clinical, workplace, and monitoring settings for initial detection across multiple drug classes.

Urine
Urine Collection
Also Known As: Drug Monitoring Base Panel Screen Urine
Add to